tiprankstipranks
Advertisement
Advertisement

Prestige Consumer to Acquire Breathe Right Brand Portfolio

Story Highlights
  • Prestige agreed on March 19, 2026 to buy Breathe Right and other OTC brands for $1.045 billion, adding a leading global nasal strip franchise that posted $200 million in revenue and $95 million of EBITDA in 2025.
  • The deal, funded with cash and a new term loan, will lift Prestige’s leverage to about 4.0x at close but is touted as immediately accretive and supported by strong free cash flow, with a target of reducing leverage below 3.0x by fiscal 2028, pending regulatory approval and expected closing in early fiscal 2027.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Prestige Consumer to Acquire Breathe Right Brand Portfolio

Claim 55% Off TipRanks

Prestige Consumer Healthcare ( (PBH) ) has provided an announcement.

On March 19, 2026, Prestige Brands, Inc., a wholly owned unit of Prestige Consumer Healthcare, signed an asset purchase agreement to acquire from Foundation Consumer Brands a portfolio of over-the-counter health products centered on Breathe Right nasal strips for $1.045 billion in cash. The acquired portfolio generated about $200 million of revenue and $95 million of EBITDA in the 12 months to Dec. 31, 2025, and would make Breathe Right Prestige’s largest brand, adding a leading global “better breathing” franchise with significant international exposure.

Prestige plans to fund the transaction with cash and a new term loan, implying pro forma net leverage of roughly 4.0 times at closing and a planned return to below 3.0 times by fiscal 2028, supported by what the company describes as strong free cash flow. Management is positioning the deal as immediately accretive to revenue, margins, earnings and free cash flow, and as a scale-enhancing move that strengthens Prestige’s competitive position in consumer health, although completion remains subject to antitrust clearance and other customary closing conditions, with closing expected in the first half of fiscal 2027.

The most recent analyst rating on (PBH) stock is a Buy with a $77.00 price target. To see the full list of analyst forecasts on Prestige Consumer Healthcare stock, see the PBH Stock Forecast page.

Spark’s Take on PBH Stock

According to Spark, TipRanks’ AI Analyst, PBH is a Outperform.

PBH scores well on financial performance driven by strong cash flow and healthy margins, supported by constructive (but not fully recovered) technical momentum. The earnings call reinforces cash-flow durability and margin improvement, but the overall score is held back by ongoing revenue softness tied to supply constraints and a mid-range valuation with no dividend yield provided.

To see Spark’s full report on PBH stock, click here.

More about Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc. is a U.S.-based over-the-counter consumer healthcare company whose portfolio spans branded products in categories such as cold relief, oral analgesics and other everyday health remedies. The group focuses on acquiring and scaling established consumer brands, with a strategy built around high gross margins, strong cash generation and disciplined leverage management.

Average Trading Volume: 387,354

Technical Sentiment Signal: Sell

Current Market Cap: $2.84B

For detailed information about PBH stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1